Skip to main content
Journal cover image

Randomized phase III trial of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLDOX) for patients (pts.) with platinum-resistant (pt-r) ovarian cancer (oc) undergoing second or third-line chemotherapy (ct)

Publication ,  Conference
Mutch, D; Orlando, M; Teneriello, T; Gordon, A; McMeekin, S; Goss, T; Scribner, D; Naumann, R; Secord, AA; Wang, Y
Published in: EJC SUPPLEMENTS
October 1, 2005

Duke Scholars

Published In

EJC SUPPLEMENTS

ISSN

1359-6349

Publication Date

October 1, 2005

Volume

3

Issue

2

Start / End Page

262 / 262

Publisher

PERGAMON-ELSEVIER SCIENCE LTD

Related Subject Headings

  • Oncology & Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mutch, D., Orlando, M., Teneriello, T., Gordon, A., McMeekin, S., Goss, T., … Wang, Y. (2005). Randomized phase III trial of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLDOX) for patients (pts.) with platinum-resistant (pt-r) ovarian cancer (oc) undergoing second or third-line chemotherapy (ct). In EJC SUPPLEMENTS (Vol. 3, pp. 262–262). PERGAMON-ELSEVIER SCIENCE LTD.
Mutch, D., M. Orlando, T. Teneriello, A. Gordon, S. McMeekin, T. Goss, D. Scribner, R. Naumann, A Alvarez Secord, and Y. Wang. “Randomized phase III trial of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLDOX) for patients (pts.) with platinum-resistant (pt-r) ovarian cancer (oc) undergoing second or third-line chemotherapy (ct).” In EJC SUPPLEMENTS, 3:262–262. PERGAMON-ELSEVIER SCIENCE LTD, 2005.
Mutch D, Orlando M, Teneriello T, Gordon A, McMeekin S, Goss T, et al. Randomized phase III trial of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLDOX) for patients (pts.) with platinum-resistant (pt-r) ovarian cancer (oc) undergoing second or third-line chemotherapy (ct). In: EJC SUPPLEMENTS. PERGAMON-ELSEVIER SCIENCE LTD; 2005. p. 262–262.
Mutch D, Orlando M, Teneriello T, Gordon A, McMeekin S, Goss T, Scribner D, Naumann R, Secord AA, Wang Y. Randomized phase III trial of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLDOX) for patients (pts.) with platinum-resistant (pt-r) ovarian cancer (oc) undergoing second or third-line chemotherapy (ct). EJC SUPPLEMENTS. PERGAMON-ELSEVIER SCIENCE LTD; 2005. p. 262–262.
Journal cover image

Published In

EJC SUPPLEMENTS

ISSN

1359-6349

Publication Date

October 1, 2005

Volume

3

Issue

2

Start / End Page

262 / 262

Publisher

PERGAMON-ELSEVIER SCIENCE LTD

Related Subject Headings

  • Oncology & Carcinogenesis